US FDA's Ebola Drug Approvals Showcase Efficiencies With Master Protocols
Executive Summary
Agency approved Regeneron’s monoclonal antibody cocktail Inmazeb and Ridgeback’s mAB Ebanga on data from a multi-arm, adaptive trial in which several investigational agents were independently compared to a control group. Efficacy for both drugs was demonstrated on a mortality endpoint, with lingering uncertainties to be addressed through postmarketing studies.
You may also be interested in...
US FDA Integrated Assessment Roll-Out Expanding By End Of 2021
All NMEs and original BLAs are expected to adhere to the team-based review approach by the end of the year, with expansion to other application types later.
Inmazeb Clinical Development Timeline
Chronicle of the development and review of Regeneron’s REGN-EB3, a triple mAB combination treatment for Ebola infection.
Inmazeb Clinical Development Timeline
Chronicle of the development and review of Regeneron’s REGN-EB3, a triple mAB combination treatment for Ebola infection.